Johannes Gutenberg-Universität Mainz
- 6131/39-0
Reuss, Stefan; Balmaceda, Daniel; Elgurt, Mirra et al.
Neuronal Cytoglobin in the Auditory Brainstem of Rat and Mouse: Distribution, Cochlear Projection, and Nitric Oxide ProductionBRAIN SCIENCES. Bd. 13. H. 1. 2023
Schlegelmilch, Anna-Lena; Schillner, Miriam; Zipp, Frauke et al.
Neuronal intracellular calcium storage release upon direct T-cell-neuron interactionMULTIPLE SCLEROSIS JOURNAL. Bd. 29. 2023 S. 497-498
Schaenzer, Anne; Dittmayer, Carsten; Weis, Joachim et al.
Neuropathology II: diseases of the central and peripheral nervous systems Outlook on new techniques in electron microscopyPATHOLOGIE. Bd. 44. H. 2. 2023 S. 113-119
Wu, Linda; Fulgenzi, Claudia A. M.; D'Alessio, Antonio et al.
Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev).JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. 2023 S. 504-504
Ugurel, Selma; Schmidberger, Heinz
New trends in melanoma From adjuvant therapy in stage II to novel treatment strategies with ImmTACsONKOLOGIE. Bd. 29. H. 8. 2023 S. 656-659
Giampaolo, Sabrina; Chiarolla, Cristina M.; Knoepper, Konrad et al.
NFATc1 induction by an intronic enhancer restricts NKT yδ cell formationISCIENCE. Bd. 26. H. 3. 2023
Drysdale, Simon B.; Cathie, Katrina; Flamein, Florence et al.
Nirsevimab for Prevention of Hospitalizations Due to RSV in InfantsNEW ENGLAND JOURNAL OF MEDICINE. Bd. 389. H. 26. 2023 S. 2425-2435
Schildknecht, Stefan; Daiber, Andreas
NITRIC OXIDE AND SUPEROXIDE - THE YIN AND YANG OF CARDIOVASCULAR BIOLOGYFREE RADICAL BIOLOGY AND MEDICINE. Bd. 201. 2023 S. 34-35
Daiber, Andreas; Schildknecht, Stefan
Nitric oxide, superoxide and peroxynitrite - shaping the cardiovascular environment by nitro-oxidative stress and S-nitros(yl)ationFREE RADICAL BIOLOGY AND MEDICINE. Bd. 208. 2023 S. S16-S16
Janjigian, Yelena Y.; Shitara, Kohei; Moehler, Markus H. et al.
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 16. 2023